Wells Fargo analyst Mohit Bansal raised the firm’s price target on Pfizer to $30 from $28 and keeps an Equal Weight rating on the shares. The firm says Pfizer’s Q2 raise was not totally unexpected, and per Pfizer, it was 70% operational and 30% taxes. Looking forward, medium to long term growth challenges keep Wells on the sidelines as it does not see much upside from current valuation.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- PFE Earnings: Pfizer Blows Past Estimates in Q2
- Options Volatility and Implied Earnings Moves Today, July 30, 2024
- Notable companies reporting before tomorrow’s open
- Pfizer (NYSE:PFE) Q2 Earnings Preview: Here’s What to Expect
- Options Volatility and Implied Earnings Moves This Week, July 29 – August 02, 2024
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue